Somatropin (recombinant hGH) vs CJC-1295

The distinction that mattersMarketing often implies these are equivalent. CJC-1295 has phase 1 data only; somatropin has decades of trials and a specific federal law governing its distribution.

These are not equivalent in evidence Somatropin (recombinant hGH) is rated 5/5 and CJC-1295 is rated 2/5 — a gap of 3 levels on our scale. Similar marketing does not mean similar proof.

	Somatropin (recombinant hGH) FDA Approved	CJC-1295 Research Use Only
Evidence rating	5/5 Very strong Evidence rating 5 out of 5: Very strong	2/5 Limited Evidence rating 2 out of 5: Limited
Regulatory status	FDA-approved for growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, short bowel syndrome and several other indications. Distribution for anti-aging use is specifically prohibited by US federal law.	Investigational; clinical development discontinued. Not approved. Widely sold grey-market.
Category	Growth Hormone Axis	Growth Hormone Axis
Drug class	191-amino-acid recombinant human growth hormone — a protein, not a short peptide	GHRH analog; the DAC version bears a maleimide linker that binds serum albumin
Route	Subcutaneous, daily (or weekly for long-acting analogs)	Subcutaneous (research)
Half-life	~3–4 hours subcutaneously	Non-DAC ~30 minutes; with DAC roughly 6–8 days
Studied in	Decades of randomized trials across pediatric and adult deficiency states; large post-marketing safety registries such as KIGS and NordiNet.	Small phase 1 pharmacokinetic and safety studies in healthy adults; development halted.
Who should avoid it	Active malignancy Acute critical illness — a trial in ICU patients found increased mortality Proliferative diabetic retinopathy Closed epiphyses when used for height Anti-aging or performance use	Active or prior malignancy Pregnancy Diabetes or insulin resistance Anyone in tested sport
Legal status	Prescription drug. US federal law (21 U.S.C. § 333(e)) prohibits distribution for any use other than approved indications, making anti-aging distribution a criminal offence.	Not approved for human use in the US, EU or UK. Sale for human consumption is unlawful.

Benefits — Somatropin (recombinant hGH)

Restores growth in deficient children
Unambiguous, dose-dependent improvement in growth velocity and final adult height — the indication it was developed for.
Body composition in adult deficiency
Reduces fat mass and increases lean mass in genuine adult GH deficiency, with improved quality-of-life scores.
Bone density improvement
Increases bone mineral density over multi-year treatment in deficient adults.
Multiple rare disease indications
Turner syndrome, Prader-Willi syndrome, SHOX deficiency and others, each with dedicated trial evidence.

Benefits — CJC-1295

Sustained GH and IGF-1 elevation
Phase 1 data showed multi-day increases in GH and IGF-1 after a single DAC dose — the pharmacology works as designed.
Reduced injection frequency
The DAC version requires weekly rather than daily dosing.
Synergy with ghrelin agonists
Combining a GHRH analog with a GHRP produces a larger GH pulse than either alone — well established in pituitary physiology.

Risks & cons — Somatropin (recombinant hGH)

Distributing it for anti-aging is a federal crime in the US
GH is unusual: federal law restricts distribution to approved indications specifically, and prosecutions of anti-aging clinics have followed. This is not a grey area.
Insulin resistance and diabetes
GH is directly counter-regulatory to insulin. New-onset type 2 diabetes is a recognised consequence of sustained therapy.
Fluid retention, arthralgia and carpal tunnel
Dose-related and common in adults, sometimes limiting treatment.
Intracranial hypertension
Uncommon but serious; presents with headache and visual change and requires prompt assessment.
Slipped capital femoral epiphysis in children
A recognised orthopedic complication requiring surveillance during pediatric treatment.

Risks & cons — CJC-1295

Continuous GH exposure is non-physiological
Natural GH is pulsatile. Chronic flat elevation is the pattern seen in acromegaly, and its long-term consequences with this drug are untested.
Development discontinued
The sponsor stopped work; no phase 2 or 3 efficacy or safety data exist.
Insulin resistance and glucose elevation
Expected with sustained GH/IGF-1 elevation.
Fluid retention, paraesthesia, carpal tunnel
GH-excess symptoms reported by users.
Theoretical cancer promotion
IGF-1 is mitogenic; chronic elevation in people with occult neoplasia is a genuine unknown.

Infographic for Somatropin (recombinant hGH)

A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.